1 |
Nandi A, Chen ZJ, Patel R, et al. Polycystic ovary syndrome[J]. Endocrinol Metab Clin N Am, 2014, 43(1): 123-147.
|
2 |
Zununi Vahed S, Nakhjavani M, Etemadi J, et al. Altered levels of immune-regulatory microRNAs in plasma samples of patients with lupus nephritis[J]. BioImpacts, 2018, 8(3): 177-183.
|
3 |
Záveský L, Jandáková E, Weinberger V, et al. Ovarian cancer: differentially expressed microRNAs in tumor tissue and cell-free ascitic fluid as potential novel biomarkers[J]. Cancer Invest, 2019, 37(9): 440-452.
|
4 |
Jiang JJ, Gao SS, Zhang Y. Therapeutic effects of dimethyldiguanide combined with clomifene citrate in the treatment of polycystic ovary syndrome[J]. Revista Da Assoc Med Brasileira 1992, 2019, 65(9): 1144-1150.
|
5 |
Chen Z, Ou H, Wu H, et al. Role of microRNA in the pathogenesis of polycystic ovary syndrome[J]. DNA Cell Biol, 2019, 38(8): 754-762.
|
6 |
Concha CF, Sir PT, Recabarren SE, et al. Epigenetics of polycystic ovary syndrome[J]. Rev Med Chil, 2017, 145(7): 907-915.
|
7 |
Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline[J]. J Clin Endocrinol Metab, 2013, 98(12): 4565-4592.
|
8 |
Xin H, Wang C, Liu Z. miR-196a-5p promotes metastasis of colorectal cancer via targeting IκBα[J]. BMC Cancer, 2019, 19(1): 30.
|
9 |
Pan Y, Shu X, Sun L, et al. miR‑196a‑5p modulates gastric cancer stem cell characteristics by targeting Smad4[J]. Int J Oncol, 2017, 50(6): 1965-1976.
|
10 |
Bao M, Pan S, Yang W, et al. Serum miR-10a-5p and miR-196a-5p as non-invasive biomarkers in non-small cell lung cancer[J]. Int J Clin Exp Pathol, 2018, 11(2): 773-780.
|
11 |
Zhao H, Yu H, Zheng J, et al. Lowly-expressed lncRNA GAS5 facilitates progression of ovarian cancer through targeting miR-196-5p and thereby regulating HOXA5[J]. Gynecol Oncol, 2018, 151(2): 345-355.
|
12 |
Dumesic DA, Lobo RA. Cancer risk and PCOS[J]. Steroids, 2013, 78(8): 782-785.
|
13 |
Harris HR, Babic A, Webb PM, et al. Polycystic ovary syndrome, oligomenorrhea, and risk of ovarian cancer histotypes: evidence from the Ovarian Cancer Association Consortium[J]. Cancer Epidemiol Biomarkers Prev, 2018, 27(2):174-182.
|
14 |
Harris HR, Terry KL. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review[J]. Fertil Res Pract, 2016, 2: 14.
|
15 |
Jiao J, Sagnelli M, Shi B, et al. Genetic and epigenetic characteristics in ovarian tissues from polycystic ovary syndrome patients with irregular menstruation resemble those of ovarian cancer[J]. BMC Endocr Disord, 2019, 19(1): 30.
|
16 |
Yan TH, Qiu C, Sun J, et al. miR-877-5p suppresses cell growth, migration and invasion by targeting cyclin dependent kinase 14 and predicts prognosis in hepatocellular carcinoma[J]. Eur Rev Med Pharmacol Sci, 2018, 22(10): 3038-3046.
|
17 |
Cheng C, Zhang ZC, Cheng FL, et al. Exosomal lncRNA RAMP2-AS1 derived from chondrosarcoma cells promotes angiogenesis through miR-2355-5p/VEGFR2 axis[J]. Oncotargets Ther, 2020, 13: 3291-3301.
|
18 |
Zhang Q, Guan F, Fan T, et al. LncRNA WDFY3-AS2 suppresses proliferation and invasion in oesophageal squamous cell carcinoma by regulating miR-2355-5p/SOCS2 axis[J]. J Cell Mol Med, 2020, 24(14): 8206-8220.
|
19 |
Iacomino G, Russo P, Stillitano I, et al. Circulating microRNAs are deregulated in overweight/obese children: preliminary results of the Ⅰ.Family study[J]. Genes Nutr, 2016, 11(1): 1-9.
|
20 |
Wang W, Yin Y, Shan X, et al. The value of plasma-based MicroRNAs as diagnostic biomarkers for ovarian cancer[J]. Am J Med Sci, 2019, 358(4): 256-267.
|
21 |
Guo L, Li YW, Zhao C, et al. RECQL4, negatively regulated by miR-10a-5p, facilitates cell proliferation and invasion via MAFB in ovarian cancer[J]. Front Oncol, 2020, 10: 524128.
|
22 |
Zota AR, Geller RJ, VanNoy BN, et al. Phthalate exposures and microRNA expression in uterine fibroids: the FORGE study[J]. Epigenetics Insights, 2020, 13: 2516865720904057.
|
23 |
Guo T, Zhang J, Yao W, et al. CircINHA resists granulosa cell apoptosis by upregulating CTGF as a CeRNA of miR-10a-5p in pig ovarian follicles[J]. Biochim Biophys Acta Gene Regul Mech, 2019, 1862(10): 194420.
|
24 |
刘宏改, 张展. 结缔组织生长因子和多囊卵巢综合征的关系[J]. 河南医学研究, 2007, 16(2): 189-192.
|
25 |
Zong S, Liu X, Zhou N, et al. E2F7, EREG, miR-451a and miR-106b-5p are associated with the cervical cancer development[J]. Arch Gynecol Obstet, 2019, 299(4): 1089-1098.
|
26 |
Díaz M, Bassols J, López-Bermejo A, et al. Low circulating levels of miR-451a in girls with polycystic ovary syndrome: different effects of randomized treatments[J]. J Clin Endocrinol Metab, 2020, 105(3): e273-e281.
|
27 |
Legro RS, Feingold KR, Anawalt B, et al. Evaluation and treatment of polycystic ovary syndrome[J]. Practice, 2000, 17(3):82-85.
|
28 |
梅玲蔚, 熊正爱. 氧化应激与多囊卵巢综合征的研究进展[J]. 广东医学, 2014, 35(8): 1282-1284.
|
29 |
Wickenheisser JK, Nelson-DeGrave VL, Hendricks KL, et al. Retinoids and retinol differentially regulate steroid biosynthesis in ovarian theca cells isolated from normal cycling women and women with polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2005, 90(8): 4858-4865.
|
30 |
王虎生, 阮祥燕, 李扬璐, 等. 丙二醛、视黄醇与多囊卵巢综合征发病机制关系的探索[J]. 首都医科大学学报, 2018, 39(4): 512-516.
|
31 |
Dal-Pizzol F, Klamt F, Benfato MS, et al. Retinol supplementation induces oxidative stress and modulates antioxidant enzyme activities in rat sertoli cells[J]. Free Radic Res, 2001, 34(4): 395-404.
|
32 |
Baillargeon JP, Nestler JE. Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin?[J]. J Clin Endocrinol Metab, 2006, 91(1): 22-24.
|
33 |
Baillargeon JP, Carpentier A. Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity[J]. Fertil Steril, 2007, 88(4): 886-893.
|